9/11 Squamous Cell Carcinoma Claims: VCF Compensation & WTC Health Program Benefits

Who qualifies for 9/11 squamous cell carcinoma compensation?

Anyone diagnosed with squamous cell carcinoma following presence in the New York City exposure zone, at the Pentagon, or in Shanksville, Pennsylvania during the covered period may qualify for VCF compensation. This includes area workers, residents, students, teachers, first responders, cleanup and recovery workers, volunteers, and surviving family members of those who died from a 9/11-related squamous cell carcinoma.

Squamous cell carcinoma is the second most common skin cancer in the United States, per American Cancer Society reference data, and appears with high frequency in the 9/11 community. The dust and debris that settled on skin in the weeks and months after September 11, combined with the cumulative sun exposure typical of the general adult population, produce a large certified SCC caseload each year.

Immunocompromised claimants — including transplant recipients and those on long-term immunosuppression for other certified conditions — carry a substantially elevated risk of SCC and often present with more aggressive disease.

What types of squamous cell carcinoma are covered by the WTC Health Program?

The WTC Health Program certifies malignant squamous cell carcinoma of the skin. Coverage includes the common histologic subtypes and specific variants, distinguished primarily by cellular differentiation under the microscope and by their clinical behavior:

• Well-differentiated squamous cell carcinoma — the most common presentation, with tumor cells that closely resemble normal squamous cells. Generally the most favorable prognosis of the SCC subtypes.
• Moderately and poorly differentiated squamous cell carcinoma — increasingly abnormal cellular architecture, higher rates of recurrence, and higher metastatic potential than well-differentiated SCC.
• Acantholytic (adenoid) squamous cell carcinoma — a variant characterized by loss of cell-to-cell adhesion. More aggressive behavior than typical SCC.
• Spindle cell (sarcomatoid) squamous cell carcinoma — a rare variant with elongated tumor cells that can be difficult to distinguish from a sarcoma. Aggressive behavior and higher metastatic risk.
• Verrucous carcinoma — a well-differentiated, slow-growing subtype that resembles a large wart. Locally destructive but rarely metastasizes.
• Keratoacanthoma-type squamous cell carcinoma — a rapidly growing, dome-shaped lesion with a central keratin plug. Some regress spontaneously, but the WTC Health Program certifies these as squamous cell carcinoma when biopsied and confirmed histologically.
• Marjolin's ulcer — squamous cell carcinoma arising within a chronic wound, scar, or burn site. Rare but recognized as a distinct clinical entity, and certifiable as squamous cell carcinoma where the four-year latency and other requirements are met.

Under 42 C.F.R. §88.15, the WTCHP certifies invasive squamous cell carcinoma of the skin regardless of subtype or anatomic site. The subtype, location, and depth of invasion affect the medical treatment path and can affect economic loss compensation but do not affect certifiability.

More than 400,000 people are estimated to have been exposed to 9/11 toxins in the New York Exposure Zone alone, with additional exposures at the Pentagon and Shanksville, Pennsylvania. The dust, smoke, and debris released by the collapse of the World Trade Center contained known and suspected carcinogens including asbestos, silica, polycyclic aromatic hydrocarbons, dioxins, furans, heavy metals, and other combustion byproducts.

Skin was one of the most directly exposed organs — dust settled on the face, neck, forearms, and any uncovered surface, and prolonged contact was the norm for responders, cleanup workers, and residents returning to Lower Manhattan.

Squamous cell carcinoma arises through cumulative DNA damage in the squamous cells of the outer epidermis. Ultraviolet radiation is the most well-established cause, but chemical carcinogens — including several documented in the 9/11 dust — also contribute.

Polycyclic aromatic hydrocarbons and arsenic, both present in the WTC debris field, have long been recognized as chemical carcinogens with a documented association with squamous cell carcinoma specifically, and arsenic exposure is a classic cause of both arsenical keratoses and cutaneous SCC.

Squamous cell carcinoma often develops from precursor lesions. Actinic keratoses are the most common precursor and can progress to invasive SCC over time. Many 9/11 claimants have a long history of AKs treated by dermatology before the eventual biopsy-confirmed SCC diagnosis that supports certification. Immunosuppression — including for organ transplant, autoimmune disease, or long-term corticosteroid therapy for other conditions — substantially elevates both the incidence and the aggressiveness of SCC.

Squamous cell carcinoma does not appear immediately after exposure. There is typically a period of years between exposure and clinical detection. The WTC Health Program requires a minimum four-year latency period between first date of 9/11 exposure and first date of squamous cell carcinoma diagnosis before certification.

Certification does not require proof that 9/11 exposure was the only cause of a particular squamous cell carcinoma. Under federal law, the standard is whether the exposure was substantially likely to be a significant factor in aggravating, contributing to, or causing the condition. Fair skin, cumulative sun exposure, prior tanning bed use, immunosuppression, family history, and other established SCC risk factors are common in the 9/11 community and generally do not prevent certification.

Squamous cell carcinoma typically presents as a firm, scaly, or crusted lesion on sun-exposed skin — most commonly on the face, ears, lower lip, scalp, neck, forearms, and backs of the hands. It grows more quickly than basal cell carcinoma and is more likely to be tender, ulcerated, or bleeding. Any lesion matching the descriptions below in a person with 9/11 exposure history should be evaluated by a WTC Health Program participating dermatologist.

• A firm, red nodule or a flat lesion with a scaly, crusted surface
• A sore or lesion that ulcerates and does not heal
• A rough, scaly patch on the lip that may crack or bleed (a common site for SCC)
• A raised growth with a central depression that occasionally bleeds
• A wart-like growth that crusts and may bleed
• A new sore or raised area within an old scar, burn, or chronic wound
• Persistent scaling, itching, tenderness, or bleeding in a sun-damaged area of skin

Squamous cell carcinoma can metastasize when neglected or when arising at high-risk sites. The lip, ear, scalp, and anogenital region carry meaningfully higher metastatic rates than SCC on other sites. Immunocompromised patients — transplant recipients and those on long-term immunosuppression — are at substantially higher risk of metastatic SCC. Early detection through routine dermatology examination is the most reliable way to prevent progression to advanced or metastatic disease.

The WTC Health Program requires a minimum four-year latency period between first date of 9/11 exposure and first date of a squamous cell carcinoma diagnosis. This latency requirement is set out in federal regulation and has no exceptions. A squamous cell carcinoma diagnosed less than four years after the first date of exposure cannot be certified as 9/11-related.

Most squamous cell carcinoma claimants meet the four-year requirement on its face. If the first date of 9/11 exposure occurred in September 2001 or in the weeks and months following, squamous cell carcinomas diagnosed from that date in September 2005 forward satisfy latency. Diagnoses from 2010, 2015, or 2020 are all well past the latency threshold.

The two-year VCF registration deadline runs from the date the WTC Health Program certifies the squamous cell carcinoma as 9/11-related, not from the date of diagnosis. Registration preserves the right to file a claim; the actual claim filing deadline is October 1, 2090 for all claimants. A squamous cell carcinoma diagnosed years ago may still be eligible for certification.

What is the VCF payout for 9/11 squamous cell carcinoma?

Certified 9/11 squamous cell carcinoma qualifies claimants for free medical treatment through the WTC Health Program, and allows the claimant to submit a claim for financial compensation through the September 11th Victim Compensation Fund. The VCF's non-economic loss award for squamous cell carcinoma is published in its Non-Economic Loss Awards and Certified Conditions Fact Sheet.

Baseline non-economic loss award for squamous cell carcinoma

• Squamous cell carcinoma baseline: $90,000. Squamous cell carcinoma is compensated at the non-melanoma skin cancer baseline of $90,000 under VCF Policies & Procedures Section 2.1. This is the lower end of the VCF cancer range and reflects SCC's generally favorable prognosis when detected and treated early. The $90,000 figure applies to a certified SCC diagnosis on its own record.
• Multiple squamous cell carcinomas. Many claimants develop more than one squamous cell carcinoma over the years, particularly claimants with extensive actinic damage or immunosuppression. The VCF's non-economic loss framework is condition-based rather than lesion-based, so multiple sites of SCCs are typically compensated within the non-melanoma skin cancer framework at $90,000 rather than as separate awards. Full documentation of the history matters for the medical record and for economic loss.
• Squamous cell carcinoma with a certified [basal cell carcinoma](/cancers/basal-cell-carcinoma). Where a claimant has both a certified squamous cell carcinoma and a certified basal cell carcinoma, both fall within the non-melanoma skin cancer framework at $90,000. Compensation is not doubled by adding a second non-melanoma skin cancer diagnosis, but a full history of certified skin cancer may support a higher award under the aggregate framework where other certified conditions are also present.
• Metastatic squamous cell carcinoma. SCC that has metastasized to regional lymph nodes or distant sites is a more serious clinical picture than localized SCC. While the non-economic loss baseline remains $90,000 for a single non-melanoma skin cancer condition, metastatic SCC often supports meaningful economic loss compensation for treatment costs and lost earnings, and may support review of a higher non-economic loss award under the aggregate or extraordinary-severity framework.

Aggregate compensation with melanoma or other certified conditions

• Squamous cell carcinoma plus a certified [melanoma](/cancers/melanoma): $300,000 combined. Where a claimant has both a certified squamous cell carcinoma and a certified melanoma, the combined non-economic loss award is $300,000 across the two skin cancers. This is not $90,000 plus $250,000 — the VCF determines awards based on the combination of conditions, and weighs severity across certified conditions rather than simply adding baseline amounts.
• Aggregate up to $340,000. Where a claimant has two or more types of certified skin cancer with severe long-term side effects of the cancer or treatment, a certified skin cancer in combination with a certified non-skin cancer, or a certified skin cancer in combination with an extraordinarily severe non-cancer condition, aggregate non-economic loss compensation may reach the current VCF maximum of $340,000. The $340,000 aggregate is reserved for claims involving multiple certified cancers or multiple certified cancers alongside another certified condition of extraordinary severity.

Economic loss and wrongful death compensation

In addition to non-economic loss, the VCF may award economic loss for medical expenses, lost earnings, and other financial impacts from squamous cell carcinoma treatment. Economic loss can be meaningful in cases involving Mohs micrographic surgery on the face or lip, reconstructive surgery following extensive excision, lymph node dissection for metastatic disease, radiation therapy, immunotherapy for advanced SCC, or multiple procedures over time.

Wrongful death compensation is available to the personal representatives of individuals who died from a 9/11-related squamous cell carcinoma, most often in cases of metastatic disease or aggressive high-risk-site tumors. Attorney fees for VCF claims are capped at 10% by federal statute.

How Baione Law handles a 9/11 squamous cell carcinoma claim

Baione Law represents 9/11 squamous cell carcinoma claimants at every stage:

1. Free Case Review. The firm evaluates presence in the exposure zone, exposure category, squamous cell carcinoma diagnosis and history of any additional skin cancers or precursor lesions, and current WTCHP certification status. No cost, no obligation.
2. WTC Health Program enrollment and certification support. For claimants not yet enrolled, the firm assists with enrollment and coordinates dermatology and pathology record submission to WTCHP medical providers for certification, including for the full history of squamous cell carcinoma diagnoses.
3. VCF registration and claim filing. The firm registers the claim, files the compensation claim, and prepares the supporting documentation for the claim.
4. Medical records and impact documentation. The firm compiles the medical, economic, and non-economic loss documentation the VCF requires, particularly relevant where a claimant has metastatic SCC, multiple certified skin cancers, or a squamous cell carcinoma alongside other certified conditions.
5. Award, appeals, and amendments. After the VCF issues the award, the firm reviews it, files an appeal if warranted, and handles amendments for subsequent certified conditions, including any certification of a basal cell carcinoma or melanoma that changes the compensation framework.

Attorney fees are capped at 10% by federal statute.